FDA Grants ImmunityBio COMPANY IL-15 Super Agocizer N-803 Breakthrough Therapy Identification
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
today, ImmunityBio
(http://announced that the U.SFDA(http://awarded its IL-15 super-exciting N-803 breakthrough therapy for use in combination with BCG to treat non-muscular leachate insinuated bladder cancer (CIS) patients who had previously had poor response to BCGAbout ImmunityBio
ImmunityBio's N-803 is a new IL-15 super-exciting compoundCompared to natural non-composite IL-15 in the body, N-803 has improved pharmacokinetic properties, as well as longer-lasting and enhanced anti-tumor activity in lymphatic tissueCurrently, N-803 is treating adult Patients in NMIBC in clinicaltrial(http://Previously, the N-803 was granted fast-track by the FDAThe breakthrough therapy was identified as based on positive results obtained by N-803 in Phase1 and Phase 2 clinical trials for the treatment of CIS patientsPreviously, Phase 2 trial data published by ImmunityBio showed that 90 percent of patients with Ta/T1 papilloma/non-nipple CIS met complete remission (CR) in the subgroup of Ta/T1 papilloma/non-nipple CIS In the subgroup of high-level Ta/T1 papilloma CIS patients, 75% of patients had a stable period of up to 6 months and 54% of patients had a stable period of up to 9 months
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
